A Phase 1 Open-label Dose Escalation Study of CGX1321 in Subjects With Advanced Solid Tumors

Trial Profile

A Phase 1 Open-label Dose Escalation Study of CGX1321 in Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs CGX 1321 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Curegenix
  • Most Recent Events

    • 20 Feb 2017 Planned number of patients changed from 86 to 71.
    • 20 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top